Literature DB >> 9935306

Calcium-binding allergens: from plants to man.

R Valenta1, B Hayek, S Seiberler, A Bugajska-Schretter, V Niederberger, A Twardosz, S Natter, L Vangelista, A Pastore, S Spitzauer, D Kraft.   

Abstract

Calcium-binding proteins contain a variable number of motifs, termed EF-hands, which consist of two perpendicularly placed alpha-helics and an inter-helical loop forming a single calcium-binding site. Due to their ability to bind and transport calcium as well as to interact with a variety of ligands in a calcium-dependent manner, they fulfill important biological functions in eukaryotic cells. After parvalbumin, a three EF-hand fish allergen, calcium-binding allergens were discovered in pollens of trees. grasses and weeds and, recently, as autoallergens in man. Although only a small percentage of atopic individuals displays IgE reactivity to calcium-binding allergens, these allergens may be important because of their ability to cross-sensitize allergic individuals. Confrontation and stability++ as well as IgE recognition of calcium-binding allergens greatly depend on the presence of protein-bound calcium ions. It is thus likely that hypoallergenic derivatives of calcium-binding allergens can be engineered by recombinant DNA technology for immunotherapy++ of sensitized patients.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9935306     DOI: 10.1159/000024005

Source DB:  PubMed          Journal:  Int Arch Allergy Immunol        ISSN: 1018-2438            Impact factor:   2.749


  19 in total

Review 1.  Biology of tree pollen allergens.

Authors:  Nadine Mothes; Rudolf Valenta
Journal:  Curr Allergy Asthma Rep       Date:  2004-09       Impact factor: 4.806

2.  A molecular and proteomic investigation of proteins rapidly released from triticale pollen upon hydration.

Authors:  Mohsin A Zaidi; Stephen O'Leary; Shaobo Wu; Steve Gleddie; François Eudes; André Laroche; Laurian S Robert
Journal:  Plant Mol Biol       Date:  2012-02-26       Impact factor: 4.076

Review 3.  Relevant B cell epitopes in allergic disease.

Authors:  Anna Pomés
Journal:  Int Arch Allergy Immunol       Date:  2009-11-26       Impact factor: 2.749

Review 4.  Structural characterization of pollen allergens.

Authors:  Petra Verdino
Journal:  Clin Rev Allergy Immunol       Date:  2006-04       Impact factor: 8.667

5.  Characterization of mutants of a highly cross-reactive calcium-binding protein from Brassica pollen for allergen-specific immunotherapy.

Authors:  Tetiana Garmatiuk; Ines Swoboda; Anna Twardosz-Kropfmüller; Fabio Dall'Antonia; Walter Keller; Mohan B Singh; Prem L Bhalla; Takashi Okada; Kinya Toriyama; Milena Weber; Minoo Ghannadan; Wolfgang R Sperr; Katharina Blatt; Peter Valent; Brigitte Klein; Verena Niederberger; Mirela Curin; Nadja Balic; Susanne Spitzauer; Rudolf Valenta
Journal:  Immunobiology       Date:  2013-04-24       Impact factor: 3.144

Review 6.  Recombinant Allergens in Structural Biology, Diagnosis, and Immunotherapy.

Authors:  Angelika Tscheppe; Heimo Breiteneder
Journal:  Int Arch Allergy Immunol       Date:  2017-05-04       Impact factor: 2.749

7.  Panallergens and their impact on the allergic patient.

Authors:  Michael Hauser; Anargyros Roulias; Fátima Ferreira; Matthias Egger
Journal:  Allergy Asthma Clin Immunol       Date:  2010-01-18       Impact factor: 3.406

8.  The cross-reactive calcium-binding pollen allergen, Phl p 7, reveals a novel dimer assembly.

Authors:  Petra Verdino; Kerstin Westritschnig; Rudolf Valenta; Walter Keller
Journal:  EMBO J       Date:  2002-10-01       Impact factor: 11.598

9.  Polysensitisation to pollen due to profilin and calcium-binding protein: distribution of IgE antibodies to marker allergens in grass and birch pollen allergic rhinitis patients in southern Germany.

Authors:  G Muehlmeier; H Maier
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-07-02       Impact factor: 2.503

Review 10.  Mechanisms underlying allergy vaccination with recombinant hypoallergenic allergen derivatives.

Authors:  Birgit Linhart; Rudolf Valenta
Journal:  Vaccine       Date:  2011-11-17       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.